Compare Charles River Laboratories Intl. Inc (CRL) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Weibo Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Weibo Corp trades at $6.55 (market cap $1.56B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 9.1× Weibo Corp's market cap, and Weibo Corp pays a 9.47% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Weibo Corp for 102 Days on average.
| CRL | WB | |
|---|---|---|
Market Cap | $14.23B | $1.56B |
Volume | 1,176,885 | 812,503 |
Sector | Health | Media |
52-Week High | $310.77 | $12.37 |
52-Week Low | $149.93 | $6.33 |
Typical Hold Time | 33 Days | 102 Days |
Enterprise Value | $17.06B | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Weibo (WB) trades at $6.54, up 0.93% with bearish technical signals despite attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported mixed Q2 2026 earnings with a beat on EPS but faces declining user metrics and advertising challenges. Net cash flow turned negative in 2024 at -$694M before recovering to $408M in 2025, while revenue has remained stagnant around $1.8B annually.
WB presents as a deep-value play with strong profitability margins but limited growth visibility. The stock's upside depends on advertising recovery and user engagement stabilization, though competitive pressures and China's regulatory environment pose significant risks. Analyst consensus is divided with 41% buy ratings, reflecting uncertainty about the company's ability to reignite growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
